ACCESS Newswire Inc. reported a net loss of $1.17 million for the nine months ended September 30, 2026, compared to a net income of $4.87 million in the prior year period, which was bolstered by discontinued operations. Total revenues decreased slightly to $16.46 million from $16.82 million year-over-year, while the company maintained a cash balance of approximately $2.99 million.
Orion180 Insurance Group reported third quarter 2026 financial results, highlighted by a 32% increase in net income to $11.5 million and a 60% growth in managed premiums written to $204 million. The quarter marked the company's first as a public entity following its IPO in September 2026, with managed premiums in-force reaching $678 million.
Term
Q3 2026
“We delivered an excellent quarter across our key metrics, rapidly growing our managed premiums while significantly increasing our profitability on a year-over-year basis. In addition, we achieved a major milestone in our Company’s history by successfully completing our initial public offering. We believe our results reflect the strength, differentiation and scalability of the business model we have built over the past eight years.”
Kenneth Gregg, Chief Executive Officer of Orion180
“We are well-positioned to produce durable growth on both our top and bottom lines, which is driven by our attractive suite of homeowners solutions - including our flagship FLEX product - as well as our proprietary end-to-end MY180 tech platform, which allows us to seamlessly combine best-in-class underwriting, claims management, and real-time analytic capabilities.”
Kenneth Gregg, Chief Executive Officer of Orion180
Lumexa Imaging reported Q3 2026 financial results with revenue growing 5% to $272.0 million and net income of $7.2 million. The company reiterated its full-year revenue guidance while raising its Adjusted EPS outlook to $0.86–$0.90 due to a lower effective tax rate.
Term
Q3 2026
“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year.”
Caitlin Zulla, Chief Executive Officer of Lumexa Imaging
“We are leading a transformation in healthcare - delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”
Caitlin Zulla, Chief Executive Officer of Lumexa Imaging
Velo3D reported Q3 2026 revenue of $20.5 million, a 50% year-over-year increase, driven by strong demand in aerospace and defense sectors. The company reported a GAAP net loss of $16.7 million as it invested in scaling its new Livermore Production Campus, Forge 1, which is expected to serve as its primary manufacturing center.
Term
Q3 2026
“We delivered solid third quarter results, with revenue increasing approximately 50% year-over-year to $20.5 million and new bookings reaching $28.9 million, exceeding revenue for the quarter. These results reflect continued customer demand for our metal additive manufacturing technology and the progress we are making in executing our growth strategy.”
Arun Jeldi, Chief Executive Officer of Velo3D
“Looking ahead, Forge 1 is central to Velo3D’s next phase of growth and is expected to significantly expand our production capacity as it becomes fully operational, enabling us to pursue larger production programs and capture opportunities across aerospace, defense, space and energy.”
Gain Therapeutics reported financial results for the third quarter of 2026, highlighted by long-term Phase 1b data for rexaceract showing no motor symptom progression in Parkinson’s disease patients over 12 months. The company plans to initiate a Phase 2 clinical trial for rexaceract in Q1 2027 and select an initial therapeutic indication for its second candidate, GT-04686, by the end of 2026.
Term
Q3 2026
“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD). After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms.”
Gene Mack, President and CEO of Gain Therapeutics
“As we approach the start of the Phase 2 clinical trial of rexaceract, which we expect to initiate during Q1 2027 after confirming updates to our trial design during Q4 2026, we plan to select an initial therapeutic indication to advance GT-04686 into the clinic.”
Rigetti Computing reported Q3 2026 financial results, highlighted by $1.4 million in quarterly revenue and a strong cash position of $497.1 million. The company achieved a key technical milestone with 99.5% median two-qubit fidelity on its 108-qubit system and signed a $100 million agreement with the U.S. Department of Commerce.
Term
Q3 2026
“Rigetti delivered meaningful progress during the third quarter across system performance, technology development and strategic execution. Our Cepheus-1-108Q system achieved our goal of 99.5% median two-qubit gate fidelity, demonstrating continued performance improvement at the 100-plus-qubit level and further validating our chiplet-based approach to scaling superconducting quantum computers.”
Dr. Subodh Kulkarni, Rigetti CEO
“We also signed a definitive $100 million agreement with the U.S. Department of Commerce. Building on the progress achieved this quarter, our next major system objective is to demonstrate a 300-plus-qubit system with approximately 99.7% median two-qubit gate fidelity and gate speeds below 60 nanoseconds by mid-2028.”
B&G Foods reported third quarter 2026 financial results, featuring a 4.7% increase in net sales to $459.8 million and 5.0% growth in base business net sales. The company raised its full-year 2026 net sales and Adjusted EBITDA guidance while reporting a net loss of $32.5 million for the quarter.
Term
Q3 2026
“Third quarter and year-to-date results reflect encouraging progress across B&G Foods. We generated base business net sales growth of 5.0% in the third quarter and 1.8% year-to-date, while adjusted EBITDA increased $12.4 million, or 6.6%, year-to-date. We are encouraged by this progress and remain focused on building on it.”
Rob Mills, President and Chief Executive Officer
“As we look ahead, our priorities are clear: deliver on our 2026 commitments; build a stronger operating foundation for 2027 and beyond; accelerate productivity and cost savings; improve cash generation; and reduce leverage. We are taking deliberate actions to strengthen B&G Foods, improve financial flexibility and position our company for sustainable long-term performance.”
Alliance Laundry Holdings Inc. reported a significant increase in net income for the nine months ended September 30, 2026, reaching $190.7 million compared to $81.2 million in the prior year. This growth was driven by higher net revenues of $1.36 billion and a substantial reduction in interest expense, which fell from $121.2 million to $52.3 million year-over-year.
Kura Oncology reported Q3 2026 financial results, highlighted by $13.9 million in net product revenue for KOMZIFTI, representing 53% sequential growth. The company reached FDA alignment on a registrational study design for darlifarnib in salivary gland cancer and secured a strategic financing agreement with Oberland Capital for up to $300 million.
Term
Q3 2026
“KOMZIFTI delivered strong commercial performance this quarter, with 53% sequential revenue growth, a 30% increase in new patients starts, and continued majority share of new patient starts. We believe these results demonstrate the growing commercial potential of KOMZIFTI and provide a strong foundation as we advance ziftomenib into the substantially larger frontline AML opportunity.”
Troy Wilson, Ph.D., J.D., President and Chief Executive Officer
Grayscale Horizen Trust reported a net decrease in net assets from operations of $1.893 million for the nine months ended September 30, 2026, primarily driven by unrealized depreciation of its ZEN holdings. The Trust's net assets fell to $6.780 million from $8.673 million at the start of the year, with the Principal Market NAV per Share declining from $0.76 to $0.59.
Carlsmed reported Q3 2026 revenue of $21.6 million, a 65% increase year-over-year, driven by a 60% expansion of its surgeon user base. The company raised its full-year 2026 revenue guidance to $78-$80 million and highlighted new CMS inpatient reimbursement for its aprevo lumbar spine fusion procedure.
Term
Q3 2026
“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year.”
Mike Cordonnier, Chairman and CEO
“We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo® lumbar spine fusion procedure. Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027.”
Capricor Therapeutics reported Q3 2026 financial results and provided a regulatory update on its BLA for Deramiocel in Duchenne muscular dystrophy, which has a PDUFA date of November 22, 2026. The company ended the quarter with approximately $199 million in cash and marketable securities. Management highlighted clinical data showing a 76% slowing of upper limb decline in patients who switched to Deramiocel during the HOPE-3 open-label extension.
Term
Q3 2026
“This quarter, we took important steps forward on both our regulatory filing and our launch readiness, submitting two-year HOPE-3 OLE data in a major amendment to our BLA while advancing our manufacturing and commercial preparations. In the OLE phase, patients who switched from placebo to Deramiocel saw their upper limb decline slow by 76% compared with their year on placebo, and this past weekend our HOPE-3 cardiac results received the AHA Outstanding Research Award in Pediatric Cardiology.”
Linda Marbán, Ph.D., Capricor’s Chief Executive Officer
“As Duchenne progresses, boys and young men lose the use of their arms and hands, and with it their independence, which is what Deramiocel is designed to slow. We appreciate the FDA’s engagement throughout this review and are encouraged by the Agency’s current focus on rare disease, including its recently launched Rare Disease Framework Initiative. As we approach our PDUFA date, we remain confident in the strength of our data. With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved.”
Linda Marbán, Ph.D., Capricor’s Chief Executive Officer
Braveheart Bio reported third quarter 2026 financial results, ending the period with $503.5 million in cash and investments, providing a runway into 2029. The company highlighted 52-week clinical data for BHB-1893 in obstructive HCM and outlined an updated Phase 3 development strategy designed to simplify dosing and minimize titration.
Term
Q3 2026
“BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work. The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen.”
Travis Murdoch, M.D., President and Chief Executive Officer
Grove Collaborative reported its third quarter 2026 financial results, achieving its first quarter of positive net income since becoming a public company. While total net revenue declined 15.8% year-over-year to $36.8 million, it grew 0.7% sequentially, marking the second consecutive quarter of sequential growth. The company also narrowed its full-year 2026 revenue guidance to a range of $144 million to $146 million.
Term
Q3 2026
“Third quarter results reflect the operating discipline we have built over the past several quarters. Net Revenue grew sequentially for the second consecutive quarter to $36.8 million. We also delivered positive Adjusted EBITDA for the fourth consecutive quarter, and delivered positive Adjusted EBITDA and net income in the same quarter for the first time since becoming a publicly-traded company.”
Jeff Yurcisin, Chief Executive Officer of Grove Collaborative
Orchestra BioMed reported a significant decrease in total revenue to $0.29 million for the nine months ended September 30, 2026, compared to $2.57 million in the prior year, primarily due to the absence of partnership revenue. The company's total stockholders' equity declined from $53.6 million to $7.8 million as the accumulated deficit reached $425.8 million.
Opus Genetics reported a significant increase in net loss to $120.1 million for the nine months ended September 30, 2026, primarily driven by a $72.8 million fair value change in financial instruments. Despite the loss, the company strengthened its balance sheet through $82.9 million in financing activities, including a note purchase agreement and Series B preferred stock issuance, ending the period with $89.0 million in cash and cash equivalents.
For the nine months ended September 30, 2026, ParkerVision reported a net loss of $0.5 million and a working capital deficit of $0.8 million. The company expressed substantial doubt about its ability to continue as a going concern, noting that its liquidity is dependent on successful patent licensing, litigation settlements, and potential additional financing.
TELA Bio reported Q3 2026 revenue of $19.0 million, an 8% decrease year-over-year primarily due to lower OviTex PRS volumes. The company implemented a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million and extend its cash runway into 2028. During the quarter, the company also regained Nasdaq compliance and received 510(k) clearance for its Liora Monofilament Scaffold.
Term
Q3 2026
“My first quarter as CEO was focused on putting a plan in place to return TELA Bio to growth. I joined because I believe OviTex is best-in-class technology and that we are well positioned to win in an evolving soft tissue repair and reconstruction market.”
Heather Getz, Chief Executive Officer of TELA Bio
“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway. In the third quarter alone, we reduced our adjusted EBITDA loss by 55% versus the second quarter of 2026 while delivering sequential revenue growth in the US hernia market and continued year-over-year growth in Europe.”
Grayscale Ethereum Classic Trust reported a net asset value of $94.9 million as of September 30, 2026, a decrease from $126.0 million at year-end 2025. The Trust experienced a net loss from operations of $31.1 million for the nine months ended September 30, 2026, primarily driven by $29.5 million in unrealized depreciation of its Ethereum Classic holdings.
Achieve Life Sciences (rebranded as AchieveRx) reported third quarter 2026 financial results and provided a regulatory update on its smoking cessation drug, cytisinicline. The company remains on track to resubmit its New Drug Application (NDA) to the FDA in Q4 2026 and ended the period with $201.5 million in cash and equivalents.
Term
Q3 2026
“Becoming AchieveRx, The Quit Company, reflects our shift from a clinical-stage company to one preparing to launch what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit.”
Andrew D. Goldberg, MD, Chief Executive Officer
“Our 52-week ORCA-OL results add to the growing body of evidence supporting cytisinicline as a potential treatment option for people looking to quit smoking. With an experienced launch team and our NDA resubmission on track for later this year, we are well positioned to bring cytisinicline to people who want to quit, if it is approved.”
Ambow Education reported Q3 2026 financial results with net revenues increasing 21.4% year-over-year to $1.7 million, driven by growth in both educational programs and HybriU licensing. The company reduced its net cash used in operating activities by half during the first nine months of the year while increasing investments in R&D and marketing ahead of CES 2027.
Public Policy Holding Company reported revenue of $55.2 million for the third quarter of 2026, up from $48.8 million in the prior year period. Despite a loss from operations of $8.3 million, the company achieved a small net income of $0.2 million for the quarter, aided by a $9.8 million gain on a bargain purchase. Total assets grew to $259.8 million as of September 30, 2026, compared to $202.6 million at year-end 2025.
Grocery Outlet reported Q3 2026 financial results with net sales increasing 0.9% to $1.18 billion and a return to positive comparable store sales growth of 0.5%. Net income rose to $13.3 million, or $0.13 per diluted share, despite a 40 basis point decline in gross margin driven by product promotions and higher transportation costs.
Term
Q3 2026
“In the third quarter we returned to positive comparable store sales, driven by continued improvements to the execution of our opportunistic product offering. Traffic accelerated and basket trends again improved sequentially as we enhanced our value proposition.”
ParkerVision reported a net loss of $0.5 million for the first nine months of 2026, a significant improvement from the $7.4 million loss in the prior year period. The results were driven by a 46% reduction in operating expenses and a $3.4 million gain from the fair value adjustment of contingent payment obligations. Management also provided updates on ongoing patent litigation against Qualcomm, MediaTek, and Realtek, as well as a FOIA complaint against the National Archives.
Term
9 months ended September 30, 2026
“While we believe bifurcation of our Qualcomm case is inefficient, the appellate court's decision does not impact the merits of our case, and we are eager to pursue a jury trial on our transmitter claims as expeditiously as possible.”
Jeffrey Parker, CEO of ParkerVision
“We are looking forward to a response from the National Archives given that, to date, nearly a year since responsive documents have been identified, we have still not received any of the identified responsive documents to our request.”
Bionano Genomics reported Q3 2026 revenue of $8.3 million, a 12% increase year-over-year, driven by a 24% rise in consumables revenue. The company reiterated its full-year 2026 revenue guidance of $31 million to $33 million and highlighted progress in the clinical adoption of its optical genome mapping (OGM) technology.
Term
Q3 2026
“Our third quarter results reflect the momentum building across our business and the broader genomics community, further accelerating the adoption of optical genome mapping (OGM) in clinical and commercial settings.”
Al Luderer, Ph.D., chairman and interim chief executive officer
“Coverage and regulatory progress this quarter helped build a clearer reimbursement pathway for OGM-based testing, which we expect to support broader clinical adoption over time.”
Al Luderer, Ph.D., chairman and interim chief executive officer
Worksport Ltd. reported record Q3 2026 net sales of $7.2 million, a 44.2% increase year-over-year, driven by strong performance of its NEXUS product line. The company's net loss narrowed by 27% to $3.6 million as revenue growth significantly outpaced the increase in operating expenses. Management highlighted a 95% reduction in operating cash use since Q1 2026 as the company moves toward a just-in-time production model.
For the three months ended September 30, 2026, Grayscale Bitcoin Cash Trust reported a net increase in net assets resulting from operations of $39.3 million, driven by $40.2 million in unrealized appreciation of BCH. The Trust's net assets grew from $76.6 million at the start of the period to $115.9 million, while the Principal Market NAV per Share increased from $1.62 to $2.46.
Sally Beauty Holdings reported fiscal 2026 consolidated net sales of $3,734.6 million, a 0.9% increase driven by favorable foreign currency and a 0.5% increase in comparable sales. While consolidated net earnings grew 2.1% to $200.1 million, operating earnings saw a slight 0.4% decrease due to the absence of a prior-year gain on a headquarters sale.
SilverBox Corp V reported a net income of $6,127,724 for the nine months ended September 30, 2026, primarily driven by $7,405,656 in interest earned on investments held in the Trust Account. The company remains a shell company with $284,174,540 in Class A ordinary shares subject to possible redemption and a total shareholders' deficit of $20,552,951.
Mercury Systems reported record first quarter fiscal 2027 results with revenue of $253 million, up 12.4% year-over-year, and record bookings of $370 million. The company achieved GAAP net income of $13 million and record adjusted EBITDA of $56 million, leading management to raise its full-year fiscal 2027 outlook. Additionally, the company formalized CFO David E. Farnsworth's role as Chief Operating Officer.
Term
Q1 2027
“We delivered strong first quarter fiscal 2027 results, with record first quarter bookings, revenue, and adjusted EBITDA, and record backlog. Our first quarter results reflect robust organic growth and margins that are in-line with our target profile. Based on this solid execution, we are raising our outlook for fiscal year 2027.”